PolyPid reports Q3 EPS (37c), consensus (52c)

“This past quarter was significant for PolyPid (PYPD) as we continue to progress toward bringing D-PLEX to market,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “With our upcoming pre-NDA meeting with the FDA and our NDA submission on track for early 2026, we continue to execute on our regulatory strategy while in parallel, advancing discussions with potential U.S. partners.”